Nanocrystallization of Griseofulvin Prior to Its Tablet Formulation Improves the Drug Delivery

Main Article Content

Emmanuel O, Olorunsola
Jennifer U. Ekuma
Mbang N. Femi-Oyewo
Clifford A. Orakwe


Background: Griseofulvin belongs to Class II in the Biopharmaceutics Classification System. This study aimed at enhancing the delivery of this antifungal agent by nanocrystallizing the drug powder before the tablet formulation.


Methods: Two forms of griseofulvin nanocrystals (GRF3 and GRF2) were prepared with and without the inclusion of polysorbate 80 respectively. The two forms of the nanocrystals and the unprocessed drug (GRF1) were separately used to formulate griseofulvin tablets. Each form of the drug was formulated using two different binder concentrations (3% and 6% w/w acacia gum) employing the wet granulation method. Physical and release properties of the tablets were determined using the compendial and the non-compendial methods.


Results: The mean weight of the formulated tablets ranged from 0.31 – 0.37 g. Formulation GRF2 with 6% w/w binder concentration had the highest crushing strength of 8 kgF, GRF1 with 6% w/w binder concentration had the lowest friability of 0.15% while GRF3 with 3% w/w binder concentration had the shortest disintegration time of 9.25 min. There was no significant difference between the percent drug release from GRF3 tablets containing 3% w/w binder concentration and those containing 6% w/w concentration (cumulative drug release being 83% and 80% in 60 minutes).


Conclusion: Nanocrystallization of griseofulvin modulated with the inclusion of Polysorbate 80 enhances the delivery of the drug but higher binder concentration is required to ensure good tablet strength.


Download data is not yet available.

Article Details

How to Cite
Olorunsola, E. O., Ekuma, J. U., Femi-Oyewo, M. N., & Orakwe, C. A. (2024). Nanocrystallization of Griseofulvin Prior to Its Tablet Formulation Improves the Drug Delivery. Nigerian Journal of Pharmaceutical and Applied Science Research, 13(1), 47–54.


Shegokar R, Müller RH. Nanocrystals: Industrially feasible multifunctional formulation technology for poorly soluble actives. Int J Pharm 2010; 399(1–2): 129–139.

Olorunsola EO, Ekpeowo SU, Momoh MA; Adikwu MU. Polysorbate 80 – modulated nanocrystallization for enhancement of griseofulvin solubility. German J Pharm Biomaterials 2023; 2(4): 1-7.

Kesharwani SS, Jayarama Bhat G. Formulation and nanotechnology-based approaches for solubility and bioavailability enhancement of zerumbone. Medicina (Kaunas) 2020; 56(11): 1–13.

Dizaj S M, Vazifehasl Z, Salatin S, Adibkia K, Javadzadeh Y. Nanosizing of drugs: Effect on dissolution rate. Res Pharm Sci 2015; 10(2): 95–108.

Olorunsola EO, Edet SO, Majekodunmi SO, Attih EE. Nanocrystal formation of hydrochlorothiazide: Effect of a surfactant on the solid-state properties. Nig J Pharm Appl Sci Res 2023; 12(2): 15-21.

Shinde G, Patel M, Mehta M, Kesarla R, Bangale G. Formulation, optimization and characterization of repaglinide loaded nanocrystal for diabetes therapy. Adv Pharmaceutics 2015; Article 363061.

[ Alam MA, Al-Jenoobi FI, Al-Mohizea AM. Commercially bioavailable proprietary technologies and their marketed products. Drug Discovery Today 2013; 18(19–20): 936–949.

Kumar R. Nanotechnology based approaches to enhance aqueous solubility and bioavailability of griseofulvin. A literature survey. J Drug Deliv Sci Technol 2019; 53: 101221.

Femi-Oyewo MN, Spring MS. Studies on paracetamol crystals produced by growth in aqueous solutions. Int J Pharm 1994; 112: 17-28.

Olorunsola EO, Bhatia PG, Tytler BA, Adikwu MU. Physicosurface properties of afzelia and prosopis hemicellulosic gums: potential surface active agents. IOSR J Pharm Biol Sci. 2015; 10(4 version 3): 1 – 7.

Sidim T, Akbas H. Thermodynamic and interfacial properties of cationic Gemini surfactants in the presence of alcohols. Tenside Surfactants Detergents 2018; 55(4): 287-293.

Wang Z, Yang C, Guan D, Li J, Zhang H. Cellular proteins act as surfactants to control the interfacial behaviour and function of biological condensates. Developmental Cell 2023; 58(11): 919-932.

Mokale V, Khatumaria B, Verma U, Shimpi N, Naik J, Mishra S. Formulation and development of nanoparticles for quick and complete release of hydrochlorothiazide by nanonization technique. Micro and Nanosystems 2014; 6: 109-117.

Olorunsola EO, Tologbonse AA, Onwuka NA, Adikwu MU. Enhanced oral delivery of artemether: An application of Prosochit®. J Appl Pharm Sci. 2019; 9(4): 133-136.

Olorunsola EO, Adedokun MO, Akpabio EI. Evaluation of callinectes chitosan as a superdisintegrant in metronidazole tablet. Int J Pharm Pharm Sci 2017; 9(10): 111-118.

Aulton ME. Powder flow. In: Aulton ME, Taylor KMG (Eds.). Aulton’s Pharmaceutics – The Design and Manufacture of Medicines. 4th edition. Churchill Livingstone Elsevier; 2013.

Femi-Oyewo MN. Effect of surface-active agents on granules and compacts containing 5% sulphanilamide. Int J Pharm Tech Prod Manuf 1982; 3(8): 73-75.

Saleem M, Shahin M, Srinivas B, Begum A. Evaluation of tablets by friability apparatus. Int J Res Pharm Chem 2014; 4(4): 837-840.

Femi-Oyewo MN, Spring MS. Granulation with surfactants: The effects of the affinity of substrate for water on the properties of the resulting granules and compacts. Nig J Pharm Sci 1986; 2(2): 52-60.

Alebiowu G, Femi-Oyewo MN. Further studies on Datura metel Linn powder 1: Effect of surfactants on the granules and compacts properties. Phytother Res 1998; 12: 123-126.

Olorunsola EO, Bhatia PG, Tytler BA, Adikwu MU. Surface activity and hydrophile-lipophile balance of hydrophilic polymers from exudates of cashew and khaya plants. Int J Biol Pharm Res 2014; 5(5): 443-448.

Möschwitzer JP. Drug nanocrystals in the commercial pharmaceutical development process. Int J Pharm 2013: 453(1): 142–156.

Kelly BP. Superficial fungal infections. Pediatrics in Review 2012; 33(4).

Yesudian R, Yesudian PD, Yesudian P. Oral treatment of ringworm with griseofulvin. Clin Exp Dermatol 2021: 46(5): 993–994.